Spyre reports positive phase 2 trial results for ulcerative colitis drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. META
4. AMD
5. INFY
6. UNP
7. GOOGL
8. RNG
9. SPY
10. TMUS

Go back to Spyre reports positive phase 2 trial results for ulcerative colitis drug
(NASDAQ: SYRE) Delayed: 102.13 +2.14 (2.14%)
Previous Close $99.99    52 Week High $ 
Open $100.56    52 Week Low $ 
Day High $103.57    P/E N/A 
Day Low $98.79    EPS $ 
Volume 812,829